Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the prospective randomized nationwide AML‐2003 study by the Finnish Leukemia Group

Autor: Kolonen, Aarne1 (AUTHOR) aarne.kolonen@fimnet.fi, Sinisalo, Marjatta1 (AUTHOR), Huhtala, Heini2 (AUTHOR), Rimpiläinen, Johanna1 (AUTHOR), Rintala, Hannele1 (AUTHOR), Sankelo, Marja1 (AUTHOR), Koivunen, Elli1 (AUTHOR), Silvennoinen, Raija1 (AUTHOR), Räty, Riikka3 (AUTHOR), Ruutu, Tapani3 (AUTHOR), Volin, Liisa3 (AUTHOR), Porkka, Kimmo3 (AUTHOR), Jantunen, Esa4 (AUTHOR), Nousiainen, Tapio4 (AUTHOR), Kuittinen, Taru4 (AUTHOR), Penttilä, Karri4 (AUTHOR), Pyörälä, Marja4 (AUTHOR), Säily, Marjaana5 (AUTHOR), Koistinen, Pirjo5 (AUTHOR), Kauppila, Marjut6 (AUTHOR)
Zdroj: European Journal of Haematology. Sep2022, Vol. 109 Issue 3, p257-270. 14p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje